Liraglutide showed efficacy for NAFLD in both diabetic and non-diabetic patients, reducing liver fat, inflammation, and fibrosis markers with acceptable safety across populations.
Works without diabetesLiraglutide improves NAFLD in non-diabetic patients too — extending GLP-1 liver benefits to the majority of NAFLD patients who don't have diabetes
What the researchers found
Liraglutide: effective for NAFLD in both T2D and non-diabetic patients, reducing liver fat, inflammation, and fibrosis markers with acceptable safety across populations.
Why it matters
NAFLD affects 30% of adults, most without diabetes. Confirming GLP-1 drug efficacy in non-diabetic NAFLD patients expands treatment access enormously.
How the study worked
Study evaluating liraglutide efficacy and safety for NAFLD in patients with and without T2D.
What this study cannot tell us
Study details in full paper. NAFLD staging methods may vary.
How to read the evidence
Study evaluating liraglutide across diabetic and non-diabetic NAFLD populations.
When this study was published
Published in 2025.
The bigger picture
GLP-1 drugs for NAFLD regardless of diabetes status positions them as the first widely effective liver disease treatment.
Questions still open
- Should liraglutide be first-line for NAFLD regardless of diabetes?
- Does it work for established NASH/cirrhosis?
- How does it compare to dedicated NASH drugs in development?
Common questions
Does liraglutide help fatty liver without diabetes?
How does it help the liver?
Read the original research
Efficacy and safety of liraglutide in non-alcoholic fatty liver disease with or without type 2 diabetes: A systematic review and meta-analysis.
Diabetes, obesity & metabolism, 28(2), 1168-1178
Citation
Kong, Weihan; Fang, Buwu; Xing, Wei. (2026). Efficacy and safety of liraglutide in non-alcoholic fatty liver disease with or without type 2 diabetes: A systematic review and meta-analysis.. Diabetes, obesity & metabolism, 28(2), 1168-1178. https://doi.org/10.1111/dom.70301